SecBot SecBot

APYX

Apyx Medical Corp
Nasdaq· Surgical & Medical Instruments & Apparatus· Inc. DE· CIK 0000719135 Healthcare & Medical Devices
$2.46 +0.09 (+3.80%)
Oct 26 4:00 PM ET · prev $2.37
Market cap
$101.5M
Micro cap
Consensus
Buy
92% Buy or better · 12 analysts
Median target
$6.00
+144% · range $6.00–8.00
Next earnings
Nov 5
in 10 days · EPS est. −$0.09
1 year
−21.4%
from $3.13 · Oct 27
30 days
−1.6%
from $2.50
52-week range
$2.36–4.86
−49% from high · low Oct 8
Avg volume 20D
174.4K
Sep 30 spike 639.6K
Short interest
🔒 Subscribers only
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
5
analyzed by SecBot
SecBot read MIXED 2 reports · 90 days
Balance 0 bearish · 0 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 2/2 ·Next Earnings date, Nov 5, 2026
Strongest NEUTRAL Apyx Medical Corporation announced it will report its fiscal Q3 2026 results on November 5, 2026.
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q2 2026: 6 added (0 new), 7 trimmed or exited.

  • AnalystsBULLISH

    11 of 12 rate it Buy or better. Every target is above the price.

  • EstimatesFLAT

    Current-quarter EPS estimate −$0.092 → −$0.093 over 90 days. 4 up, 0 down in 30 days.

  • TrendDOWNTREND

    12% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
ROYCE & ASSOCIATES LPADD3,274,064$14.7M
RENAISSANCE TECHNOLOGIES LLCADD554,278$2.5M
SEI INVESTMENTS COTRIM281,029$1.3M
MARSHALL WACE, LLPDOUBLED236,466$1.1M
CITADEL ADVISORS LLCADD168,344$755.9K
NewEdge Advisors, LLCADD95,815$430.2K
JANE STREET GROUP, LLCTRIM90,771$407.6K
NORTHERN TRUST CORPTRIM78,567$352.8K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

12 analysts
Buy 92% rate it Buy or better
Strong Buy3Buy8Hold1Sell0Strong Sell0
12-month targets · 6 analysts

Price is below the lowest target. Median implies +144%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Sep 29, 2026Maxim Group
INITIATE
INITIATEBuy
Jul 13, 2026HC Wainwright & Co.
INITIATE
INITIATEBuy

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Jun 30, 2026
Waldman Lawrence
Director
EXERCISE$22.6K
Jun 30, 2026
Waldman Lawrence
Director
TAX W/H$22.6K
Jun 15, 2026
Roman Shawn David
Chief Operating Officer
EXERCISE$48.5K
Jun 15, 2026
Roman Shawn David
Chief Operating Officer
TAX W/H$48.5K
Jun 11, 2026
Waldman Lawrence
Director
AWARD50,000 sh
Jun 11, 2026
HILL MATTHEW C
Chief Financial Officer
AWARD132,066 sh
Jun 11, 2026
CITRONOWICZ MOSHE
Sr. V.P. of Operations
AWARD63,392 sh
Jun 11, 2026
Roman Shawn David
Chief Operating Officer
AWARD88,044 sh

Earnings setup

Estimates
Nov 5
reports in 10 days
−$0.09
EPS estimate, this quarter
−1%
estimate change, 90 days
4↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.09-$0.13–-$0.07+2.8%$13.3M
Next Q-$0.05-$0.07–-$0.02+10.7%$19.7M
Current FY🔒 Fresh data, subscribers only
Next FY-$0.25-$0.32–-$0.21+2.5%$66.0M

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 22, 2026 SEC
Apyx Medical Corporation announced it will report its fiscal Q3 2026 results on November 5, 2026.
PRESS-RELEASE — Impact 1/10
Oct 22, 2026 Earnings
Apyx Medical Corporation to Release Third Quarter of Fiscal Year 2026 Financial Results on November 5, 2026
CLEARWATER, Fla., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Com
Aug 7, 2026 SEC
Apyx Medical Corp held its 2026 Annual Meeting on August 6, 2026. Stockholders approved all four proposals: election…
8-K — Impact 3/10
Jun 30, 2026 Insider
Waldman Lawrence acquired via exercise 12,000 shares
Director @ $1.88 ($22.6K)
Jun 30, 2026 Insider
Waldman Lawrence surrendered for taxes 5,024 shares
Director @ $4.49 ($22.6K)
Jun 30, 2026 Inst.
ROYCE & ASSOCIATES LP — ADD
3,274,064 shares ($14.7M)
Jun 30, 2026 Inst.
RENAISSANCE TECHNOLOGIES LLC — ADD
554,278 shares ($2.5M)
Jun 15, 2026 Insider
Roman Shawn David acquired via exercise 15,000 shares
Chief Operating Officer @ $3.23 ($48.5K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 5, 2026
Earnings date
APYX Q3 2026 Earnings Before Market Open — 2026-11-05
Recent
Oct 22, 2026
Earnings
Apyx Medical Corporation to Release Third Quarter of Fiscal Year 2026 Financial Results on November 5, 2026
CLEARWATER, Fla., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in…
Aug 6, 2026
Earnings date
APYX Q2 2026 Earnings Before Market Open — 2026-08-06
Jul 23, 2026
Earnings
Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026
CLEARWATER, Fla., July 23, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical…
May 21, 2026
FDA
New Study Shows Significant Improvement in Cellulite and Skin Laxity with Advanced Minimally Invasive Treatment Utilizing Avéli® and Renuvion®
Published data demonstrates visible reduction in dimpling and progressive tissue remodeling through a single-session approach Published data…
May 11, 2026
Press release
Apyx Medical Corporation Receives Expanded FDA 510(k) Clearance Adding Power Liposuction Capability to AYON Body Contouring System™
Addition of the power liposuction capability as a second advanced liposuction modality is expected to drive even greater market demand for AYON…

SecBot reports

5 filings · 3 press releases · 1 bullish · 0 bearish · 4 neutral
All APYX filing & press-release reports (8)